Illumina Launches Cloud-Based Multiomics Platform to Enhance Biological Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Newsfilter
- Platform Launch: On January 6, 2026, Illumina introduced the Illumina Connected Multiomics platform, designed to integrate multiomic data, significantly reducing research time and costs, thereby accelerating discoveries in precision medicine.
- User Friendliness: The platform, developed with feedback from 40 early access users, ensures ease of use, allowing researchers without programming backgrounds to focus on biological insights rather than bioinformatics challenges.
- Multimodal Capabilities: Connected Multiomics supports single-cell and spatial transcriptomics analysis, providing differential expression and cell typing, which enhances the spatial context of biological insights and drives breakthroughs in biology and drug development.
- AI Integration: The platform incorporates AI-driven variant interpretation, enabling earlier identification of biologically significant multiomic signals, further enhancing the efficiency and accuracy of analyses.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 117.25 USD with a low forecast of 80.00 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
4 Buy
5 Hold
3 Sell
Hold
Current: 147.110
Low
80.00
Averages
117.25
High
195.00
Current: 147.110
Low
80.00
Averages
117.25
High
195.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
